Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Risk assessment of gene variants for neonatal hyperbilirubinemia in Taiwan

BMC PediatricsBMC series – open, inclusive and trusted201616:144

https://doi.org/10.1186/s12887-016-0685-8

Received: 24 February 2016

Accepted: 23 August 2016

Published: 24 August 2016

Abstract

Background

Hyperbilirubinemia is a common disorder during neonatal period in Taiwan. Gene variants may play an important role in the development of neonatal hyperbilirubinemia. The current study investigated the association between neonatal hyperbilirubinemia and common gene variants involving the production and metabolism of bilirubin.

Methods

This prospective study enrolled 444 healthy infants born in the Chang Gung Memorial Hospital at Taipei from 2013–2015. Hyperbilirubinemia was defined as a total bilirubin ≥ 15 mg/dL. A log-binomial model was used to assess the risk of gene variants.

Results

The most common genetic variant was short heme oxygenase (HO)-1 promoter GT-allele (<24 repeats) (39.4 %), followed by GA at nt388 in hepatic solute carrier organic anion transporter 1B1 (SLCO1B1) (31.1 %), GA at nt211 in UDP-glucuronosyltransferase 1A1 (UGT1A1) (29.3 %), ABO incompatibility (16.2 %), alpha thalassemia (5.0 %), and G6PD deficiency (3.2 %). The log-binomial analysis demonstrated greater risks of hyperbilirubinemia in infants with GA at nt211 in UGT1A1 (RR = 1.548; 95 % CI = 1.096–2.187), short HO-1 promoter GT-repeat (RR = 2.185; 95 % CI = 1.527–3.125), and G6PD deficiency (RR = 1.985; 95 % CI = 1.010–3.901). The other gene variants – including blood type, alpha thalassemia, and SLCO1B1 – carried no significant risk.

Conclusions

G6PD deficiency, short HO-1 promoter GT-repeat and GA at nt211 in UGT1A1 are risk factors of neonatal hyperbilirubinemia. The data provide clinical evidence to explain the high incidence of neonatal hyperbilirubinemia in Taiwan.

Keywords

Neonatal hyperbilirubinemia Heme oxygenase-1 UDP-glucuronosyltransferase 1A1 Thalassemia Hepatic solute carrier organic anion transporter 1B1

Background

Hyperbilirubinemia is a common disorder during neonatal period. It is associated with a variety of physiologic and pathologic conditions [1]. Common factors in relation to neonatal hyperbilirubinemia are breast milk feeding, isoimmune hemolytic disease and G6PD deficiency [25]. In addition, other gene variants – including heme oxygenase (HO)-1, hepatic solute carrier organic anion transporter 1B1 (SLCO1B1), and UDP-glucuronosyltransferase 1A1 (UGT1A1)—have been reported as risk factors of neonatal hyperbilirubinemia [69].

Asian infants are at greater risk of hyperbilirubinemia [10]. Gene variants may play an important role in the development of neonatal hyperbilirubinemia. In the current study, we examined 6 genetic variants involving the production and metabolism of bilirubin to verify their correlation with neonatal hyperbilirubinemia. Our data will provide clinical evidence to explain the high incidence of neonatal hyperbilirubinemia in Taiwan.

Methods

Study design

Healthy infants born in the Chang Gung Memorial Hospital at Taipei between January 2013 and August 2015 were eligible for enrollment. Infants with gestational age less than 35 weeks and birth weight less than 2000 g were not enrolled since they carry great risk for neonatal hyperbilirubinemia. In addition, ill neonates admitted to neonatal intensive care unit (NICU) were excluded. The Institutional Review Board of Chang Gung Memorial Hospital approved the study protocol. Informed consent was obtained from parents of enrolled infants.

Clinical measures

Infants were routinely observed visually for the development of significant clinical jaundice. Bilirubin level was screened daily in all infants with non-invasive transcutaneous bilirubinmeter BiliCheck device (Spectrx Inc, Norcross, GA, USA) [11]. Serum bilirubin tests were performed with UnistatTM bilirubinmeter (Cambridge Instruments, NY, USA). The protocol of phototherapy was modified from the guideline of 2004 American Academy of Pediatrics [12], as indicated for preterm infants < 37 weeks of gestation (≥7 mg/dL at < 24 h old, ≥ 9 mg/dL at 24–35 h old, ≥ 10 mg/dL at 36–47 h old, ≥ 12 mg/dL at 48–59 h old, ≥ 13 mg/dL at 60–71 h old, ≥ 14 mg/dL at 72–95 h old, and ≥ 15 mg/dL at ≥ 96 h old) and term infants (≥9 mg/dL at < 24 h old, ≥ 11 mg/dL at 24–35 h old, ≥ 12 mg/dL at 36–47 h old, ≥ 14 mg/dL at 48–59 h old, ≥ 15 mg/dL at 60–71 h old, ≥ 16 mg/dL at 72–95 h old, and ≥ 17 mg/dL at ≥ 96 h old). Hyperbilirubinemia was defined as total bilirubin ≥ 15 mg/dL during the hospital course [8].

Demographic data — including gender, delivery mode, birth weight and gestational age—were collected from birth records. The feeding type was classified into three categories: (1) formula feeding; (2) combination feeding of breast milk and formula, defined as at least one meal of breast milk and formula daily; (3) breast milk feeding.

Laboratory measures

This study examined the following genes – including G6PD, blood type (ABO and Rh), HO-1, UGT1A1, alpha thalassemia, and SLCO1B1. All infants were screened for G6PD deficiency on the second day of life with blood samples from heel stick as a routine part of Taiwan’s national newborn screening program. The quantitative test for G6PD activity of red blood cells was performed to confirm the diagnosis of G6PD deficiency in those who had positive results from screening [2]. Blood type (ABO and Rh) was examined using a commercially available kit (Immucor Gamma, Norcross, GA, USA).

Total genomic DNA was isolated from cord blood cells by using the Puregene DNA Isolation Kit (Qiagen, Minneapolis, MN). The polymerase chain reaction (PCR) mixture comprises 10 mM Tris (pH 9.0), 50 mM KCL, 200 mM dNTPs, 1.25 mM MgCl2, 10 pmol each of primers, 20 μl DNA and 1 U Taq DNA polymerase (Gibco BRL). PCR is carried out in an automated thermocycler with optimal conditions. Restriction fragment length polymorphism (RFLP) and sequencing from products of PCR were conducted as means of detecting the known gene variants [8].

The HO-1 promoter gene containing GT repeats was amplified by PCR with a sense primer (5’-AGA GCC TGC AGC TTC TCA GA-3’) and an antisense primer (5’-ACA AAG TCT GGC CAT AGG AC-3’) according to a published protocol [13]. PCR products were analyzed in an automated DNA sequencer (ABI Prism 377, Foster City, CA). Sizes of GT repeats were calculated using GeneScan Analysis software (PE Applied Biosystems, Foster City, CA). To detect the alpha thalassemia-1 of Southeast Asia type, PCR was performed using the following primers – (a) 5` - GCG ATC TGG GCT CTG TGT TCT - 3`; (b) 5` - GTT CCC TGA GCC CCG ACA CG - 3`; (c) 5` - ACT GCA GCC TTG AAC TCC TG - 3` [14]. In addition, SLCO1B1 gene containing nt388 variant was amplified by PCR with a sense primer (5’-ATA ATG GTG CAA ATA AAG GGG-3’) and an antisense primer (5’-ACT ATC TCA AGG TGA TGC TCT A-3’) [15]. Furthermore, UGT1A1 gene containing nt211 variant was amplified by PCR with a sense primer (5’-CTC TAA GCA CAT CCC CAA GTA-3’) and an antisense primer (5’-TAA GCA AGT TTC CAT CCT TCA-3’) [15].

Statistical analyses

The statistics were compiled using a commercially available program (SPSS 19.0 for Windows, SPSS Inc., Chicago, Illinois, USA). Categorical variables were analyzed using the chi-square test. For comparison between groups with quantitative variables, the null hypothesis that there was no difference between each group was tested by a one‐way analysis of variance (ANOVA). A log-binomial model (generalized linear model with a log link and a binomial distribution for the error term) was used to estimate the risk of neonatal hyperbilirubinemia in relation to gene variants after adjusting for possible confounders of neonatal factors – including feeding type, delivery mode, and gestational age. Relative risk with 95 % confidence intervals (CI) was expressed after adjusting for the control variables. Significance was defined as p < 0.05.

Results

Demographic information

Of the 520 parents approached for participation, 444 infants (85.4 %) were enrolled into this study. Their demographic data are listed in Table 1. The incidence of neonatal hyperbilirubinemia was 22.5 % (100/444). Only a few participants were preterm (3.6 %) and low birth weight infants (<2500 g) (0.9 %). Neonatal hyperbilirubinemia was noted in 100 infants (22.5 %). There was no significant difference in the gender, delivery mode, gestational age, birth weight, and feeding type between infants with and without hyperbilirubinemia.
Table 1

Demographic data of participants

Demographics

Hyperbilirubinemia

p value

Demographics

Yes

No

 

N = 100

N = 344

Male sex

51 (51.0 %)

185 (53.8 %)

0.624

Cesarean section

27 (27.0 %)

112 (32.6 %)

0.291

Preterm

4 (4.0 %)

12 (3.5 %)

0.809

Birth weight (g)

3211 ± 330

3226 ± 372

0.715

Feeding type

  

0.814

 Breast milk

52 (52.0 %)

192 (55.8 %)

 

 Formula

3 (3.0 %)

14 (4.1 %)

 

 Combination

45 (45.0 %)

138 (40.1 %)

 

Correlation of gene variants with neonatal hyperbilirubinemia

According to the classification of previous reports [16, 17], we divided the number of GT alleles into two categories: short (<24 repeats) and long (≥24 repeats) alleles. In total, the most common genetic variant was short HO-1 promoter GT-repeat (39.4 %), followed by GA at nt388 in SLCO1B1 (31.1 %), GA at nt211 in UGT1A1 (29.3 %), ABO incompatibility (defined as neonates with A or B blood type born to type O mothers [18]) (16.2 %), alpha thalassemia (5.0 %), G6PD deficiency (3.2 %), and Rh negative (0 %).

Table 2 illustrates the correlation of gene variants with neonatal hyperbilirubinemia. There was a significant correlation of neonatal hyperbilirubinemia with HO-1 promoter GT-repeat and nt211 in UGT1A1. Short HO-1 promoter GT-repeat and GA at nt211 in UGT1A1 were at greater risk of hyperbilirubinemia.
Table 2

Correlation of gene variants with neonatal hyperbilirubinemia by univariate analysis

Gene variant

Hyperbilirubinemia

p value

Yes

No

N = 100

N = 344

ABO incompatibility

17 (17.0 %)

55 (16.0 %)

0.809

G6PD deficiency

6 (6.0 %)

8 (2.3 %)

0.096

Alpha thalassemia

4 (4.0 %)

18 (5.2 %)

0.796

UGT1A1 (nt211)

  

0.015

 GA

39 (39.0 %)

91 (26.5 %)

 

 GG

61 (61.0 %)

253 (73.5 %)

 

SLCO1B1 (nt388)

  

0.449

 GA

28 (28.0 %)

110 (32.0 %)

 

 GG

72 (72.0 %)

234 (68.0 %)

 

HO-1 promoter (GT)n allele

   

 < 24 repeats (short)

59 (59.0 %)

116 (33.7 %)

<0.001

 ≥ 24 repeats (long)

41 (41.0 %)

228 (66.3 %)

 

Risk assessment by a log-binomial model

A log-binomial analysis to assess the risk of hyperbilirubinemia is shown in Table 3. There were greater risks of neonatal hyperbilirubinemia in infants with G6PD deficiency, short HO-1 promoter allele, and GA at nt211 in UGT1A1.
Table 3

Risk assessment of gene variants for neonatal hyperbilirubinemia by log-binomial analysis (n = 444)

Gene variant

Relative risk

95 % CI

p value

ABO incompatibility

1.075

0.685–1.687

0.754

G6PD deficiency

1.985

1.010–3.901

0.047

Alpha thalassemia

0.619

0.252–1.519

0.295

GA at nt211 in UGT1A1

1.548

1.096–2.187

0.013

GA at nt388 in SLCO1B1

0.921

0.627–1.353

0.675

Short HO-1 promoter GT-repeat

2.185

1.527–3.125

<0.001

Discussion

The current study depicts the correlation of gene variants with neonatal hyperbilirubinemia in Taiwan. We used a log-binomial model to control the possible confounding factors. In addition, our study investigated six different genes involving the production and metabolism of bilirubin. Furthermore, we selected common gene variants in an attempt to explain the high incidence of neonatal hyperbilirubinemia in Taiwan. The data showed 3 gene variants – including G6PD deficiency, GA at nt211 in UGT1A1, and short HO-1 promoter GT-repeat – carried great risks for hyperbilirubinemia. To our knowledge, our study is the first prospective survey to determine the correlations of neonatal hyperbilirubinemia with HO-1 promoter GT-repeat and alpha-thalassemia in Taiwan.

HO is the rating-limiting enzyme to catalyze heme into bilirubin [19]. HO-1, one of HO isoforms, has been regarded as an inducible antioxidant [20]. The size of GT-repeat alleles in the HO-1 promoter can alter the inducibility of HO-1 [21]. Thus, a number of studies tried to verify the association between HO-1 promoter GT-repeat and neonatal jaundice. However, the results are still controversial [7, 16, 17, 2225]. In our study, HO-1 promoter GT allele was relevant to neonatal hyperbilirubinemia. Our data demonstrated short HO-1 promoter GT-repeat is the most common gene variant. Thus, we speculate gene variants of HO-1 promoter GT allele contribute to the high prevalence of neonatal hyperbilirubinemia in the population of Taiwan.

UGT1A1 is an enzyme responsible for bilirubin conjugation. A missense mutation of G to A at nt211 in UGT1A1 is common [26]. Our study demonstrated that GA at nt211 in UGT1A1 is associated with neonatal hyperbilirubinemia, which is consistent with a number of previous reports [8, 2628]. However, a correlation of GA at nt211 in UGT1A1 with neonatal hyperbilirubinemia was not noted in Caucasian population [27, 29]. Further study is needed to verify the difference between ethnicities.

It’s well documented that G6PD deficiency is a risk factor of neonatal hyperbilirubinemia [2, 3, 12]. In our study, the incidence of G6PD deficiency in infants with hyperbilirubinemia was 2.6-fold higher than that of infants without hyperbilirubinemia. However, the univariate analysis did not show a statistical difference. Nevertheless, the log-binomial analysis demonstrated a significant correlation of G6PD deficiency with neonatal hyperbilirubinemia after adjusting other confounding factors. In our study, infants with G6PD deficiency are at an increased risk for hyperbilirubinemia in the first few days of life even in the hospital free from agents that can potentially cause destruction of G6PD-deficient red cells. The data support our previous report in a large scale of population showing that neonatal hyperbilirubinemia in relation to G6PD deficiency is not associated with hemolysis [2].

SLCO1B1, also named as OATP2, is responsible for the transportation of unconjugated bilirubin. A relationship between nt388 in SLCO1B1 and neonatal hyperbilirubinemia has been documented [15, 30]. However, such correlation is in debate [8]. In this study, we did not find significant correlation of nt388 in SLCO1B1 with hyperbilirubinemia.

Our data indicate alpha thalassemia is not a risk factor of hyperbilirubinemia. The finding is similar to a retrospective report showing the incidence of hyperbilirubinemia was lower in the infants with alpha thalassemia [31]. We speculate that the destruction of red cells in infant with alpha thalassemia was decreased as a result of insufficient production of red cells. Therefore, their production of bilirubin was lower than infants without alpha thalassemia.

Blood group mismatch between a mother and newborn carries a substantial risk for neonatal hyperbilirubinemia [18]. However, we did not find blood group incompatibility as a significant factor of hyperbilirubinemia. We speculate three possible reasons. First, Rh incompatibility is very rare in Taiwan. Second, hemolytic anemia is not common in ABO incompatibility. Third, early phototherapy may reduce the development of hyperbilirubinemia. Therefore, we found a discrepancy of genetic influence between phototherapy and hyperbilirubinemia (data not shown). Taken together, we suggest that blood group incompatibility has only mild impact on the high incidence of neonatal hyperbilirubinemia in Taiwan.

A couple of methodological issues should be cautiously interpreted in this study. First, the sample size was relatively small in infants with hyperbilirubinemia. Nevertheless, the statistical power using the GPower 3.1 program to detect a significant association in HO-1 promoter allele was 99.1 %, which indicating sufficient power to achieve a low risk of type II error. Second, we enrolled infants whose parents were willing to participating in this study. One would question whether the gene variants in this design carry expected frequency. We believe the selection bias is minimal because of similar frequency with previous reports in Taiwan [2, 8, 13, 14, 18, 26].

Conclusions

There are some critical findings in this study. We show G6PD deficiency, GA at nt211 in UGT1A1, and short HO-1 promoter GT-repeat possess great risks for neonatal hyperbilirubinemia. In contrast, the other 3 gene variants – including alpha thalassemia, blood group incompatibility, and SLCO1B1—are not related to hyperbilirubinemia. The findings suggest that a high incidence of neonatal hyperbilirubinemia in Taiwan may be derived from high prevalence of gene variants in G6PD, nt211 in UGT1A1, and HO-1 promoter GT-repeat. Overall, our data provide clinical implication of identifying infants at great risk of neonatal hyperbilirubinemia. Early intervention and close monitor are helpful in reducing severe hyperbilirubinemia for infants with G6PD deficiency, short HO-1 promoter GT-repeat, and GA at nt211 in UGT1A1.

Abbreviation

HO-1: 

Heme oxygenase-1

nt: 

nucleotide

PCR: 

Polymerase chain reaction

SLCO1B1: 

Hepatic solute carrier organic anion transporter 1B1

UGT1A1: 

UDP-glucuronosyltransferase 1A1

Declarations

Acknowledgements

We are grateful to the participants who gave their time in this study. This work was supported by research grants from Chang Gung Memorial Hospital (CMRPG1B0131, CMRPG1B0132) and Ministry of Science and Technology (MOST 104-2314-B-182A-138-, MOST 104-2410-H-038-006-SSS). The authors thank Yueh-Jung Chen for her dedicated work on the collection of research data and laboratory analysis

Funding

This work was supported by research grants from Chang Gung Memorial Hospital (CMRPG1B0131, CMRPG1B0132) and Ministry of Science and Technology (MOST 104-2314-B-182A-138-, MOST 104-2410-H-038-006-SSS).

Availability of data and materials

Data and materials are not available due to the policy of the Institutional Review Board of Chang Gung Memorial Hospital.

Authors’ contributions

YHW and YWC conceived and developed the study. SWC and CYY assisted with coordinating the study and participated in data collection. YHW and YWC were responsible for the statistical analysis. All the authors were involved in drafting the manuscript. The final manuscript was read and approved by all the authors.

Competing interests

The authors declare that they have no competing interests.

Consent for publication

All of the authors grant the publisher permission to publish their work.

Ethics approval and consent to participate

The Institutional Review Board of Chang Gung Memorial Hospital approved the study protocol. Informed consent was obtained from parents of enrolled infants.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Division of Neonatology, Department of Pediatrics, Chang Gung Memorial Hospital, Chang Gung University College of Medicine
(2)
Master Program in Global Health and Development, College of Public Health and Nutrition, Taipei Medical University
(3)
Department of Public Health, Kaohsiung Medical University

References

  1. Dennery PA, Seidman DS, Stevenson DK. Neonatal hyperbilirubinemia. N Engl J Med. 2001;344(8):581–90.View ArticlePubMedGoogle Scholar
  2. Weng YH, Chou YH, Lien RI. Hyperbilirubinemia in healthy neonates with glucose-6-phosphate dehydrogenase deficiency. Early Hum Dev. 2003;71(2):129–36.View ArticlePubMedGoogle Scholar
  3. Weng YH, Chiu YW. Clinical characteristics of G6PD deficiency in infants with marked hyperbilirubinemia. J Pediatr Hematol Oncol. 2010;32(1):11–4.View ArticlePubMedGoogle Scholar
  4. Gourley GR. Breast-feeding, neonatal jaundice and kernicterus. Semin Neonatol. 2002;7(2):135–41.View ArticlePubMedGoogle Scholar
  5. Cheng SW, Chiu YW, Weng YH. Etiological analyses of marked neonatal hyperbilirubinemia in a single institution in Taiwan. Chang Gung Med J. 2012;35(2):148–54.PubMedGoogle Scholar
  6. Maruo Y, Morioka Y, Fujito H, Nakahara S, Yanagi T, Matsui K, Mori A, Sato H, Tukey RH, Takeuchi Y. Bilirubin uridine diphosphate-glucuronosyltransferase variation is a genetic basis of breast milk jaundice. J Pediatr. 2014;165(1):36–41. e31.View ArticlePubMedPubMed CentralGoogle Scholar
  7. Tiwari PK, Sethi A, Basu S, Raman R, Kumar A. Heme oxygenase-1 gene variants and hyperbilirubinemia risk in North Indian newborns. Eur J Pediatr. 2013;172(12):1627–32.View ArticlePubMedGoogle Scholar
  8. Chang PF, Lin YC, Liu K, Yeh SJ, Ni YH. Identifying term breast-fed infants at risk of significant hyperbilirubinemia. Pediatr Res. 2013;74(4):408–12.View ArticlePubMedGoogle Scholar
  9. Chou HC, Chen MH, Yang HI, Su YN, Hsieh WS, Chen CY, Chen HL, Chang MH, Tsao PN. 211G to a variation of UDP-glucuronosyl transferase 1A1 gene and neonatal breastfeeding jaundice. Pediatr Res. 2011;69(2):170–4.View ArticlePubMedGoogle Scholar
  10. Setia S, Villaveces A, Dhillon P, Mueller BA. Neonatal jaundice in Asian, white, and mixed-race infants. Arch Pediatr Adolesc Med. 2002;156(3):276–9.View ArticlePubMedGoogle Scholar
  11. Weng YH, Chiu YW, Cheng SW. Breast milk jaundice and maternal diet with Chinese herbal medicines. Evid Based Complement Alternat Med. 2012;2012:150120.PubMedPubMed CentralGoogle Scholar
  12. American Academy of Pediatrics Subcommittee on H. Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. Pediatrics. 2004;114(1):297–316.View ArticleGoogle Scholar
  13. Chen YH, Lin SJ, Lin MW, Tsai HL, Kuo SS, Chen JW, Charng MJ, Wu TC, Chen LC, Ding YA, et al. Microsatellite polymorphism in promoter of heme oxygenase-1 gene is associated with susceptibility to coronary artery disease in type 2 diabetic patients. Hum Genet. 2002;111(1):1–8.View ArticlePubMedGoogle Scholar
  14. Chang JG, Lee LS, Lin CP, Chen PH, Chen CP. Rapid diagnosis of alpha-thalassemia-1 of southeast Asia type and hydrops fetalis by polymerase chain reaction. Blood. 1991;78(3):853–4.PubMedGoogle Scholar
  15. Huang MJ, Kua KE, Teng HC, Tang KS, Weng HW, Huang CS. Risk factors for severe hyperbilirubinemia in neonates. Pediatr Res. 2004;56(5):682–9.View ArticlePubMedGoogle Scholar
  16. Yang H, Wang Q, Zheng L, Lin M, Zheng XB, Lin F, Yang LY. Multiple Genetic Modifiers of Bilirubin Metabolism Involvement in Significant Neonatal Hyperbilirubinemia in Patients of Chinese Descent. PLoS One. 2015;10(7), e0132034.View ArticlePubMedPubMed CentralGoogle Scholar
  17. Bozkaya OG, Kumral A, Yesilirmak DC, Ulgenalp A, Duman N, Ercal D, Ozkan H. Prolonged unconjugated hyperbilirubinaemia associated with the haem oxygenase-1 gene promoter polymorphism. Acta Paediatr. 2010;99(5):679–83.PubMedGoogle Scholar
  18. Weng YH, Chiu YW. Spectrum and outcome analysis of marked neonatal hyperbilirubinemia with blood group incompatibility. Chang Gung Med J. 2009;32:400–8.PubMedGoogle Scholar
  19. Weng YH, Yang G, Weiss S, Dennery PA. Interaction between heme oxygenase-1 and −2 proteins. Journal Biol Chem. 2003;278(51):50999–1005.View ArticleGoogle Scholar
  20. Weng YH, Tatarov A, Bartos BP, Contag CH, Dennery PA. HO-1 expression in type II pneumocytes after transpulmonary gene delivery. Am J Physiol Lung Cell Mol Physiol. 2000;278(6):L1273–1279.PubMedGoogle Scholar
  21. Yamada N, Yamaya M, Okinaga S, Nakayama K, Sekizawa K, Shibahara S, Sasaki H. Microsatellite polymorphism in the heme oxygenase-1 gene promoter is associated with susceptibility to emphysema. Am J Hum Genet. 2000;66(1):187–95.View ArticlePubMedPubMed CentralGoogle Scholar
  22. Zhou Y, Wang SN, Li H, Zha W, Peng Q, Li S, Chen Y, Jin L. Quantitative trait analysis of polymorphisms in two bilirubin metabolism enzymes to physiologic bilirubin levels in Chinese newborns. J Pediatr. 2014;165(6):1154–60. e1151.View ArticlePubMedGoogle Scholar
  23. Kaplan M, Renbaum P, Hammerman C, Vreman HJ, Wong RJ, Stevenson DK. Heme oxygenase-1 promoter polymorphisms and neonatal jaundice. Neonatology. 2014;106(4):323–9.View ArticlePubMedGoogle Scholar
  24. Katayama Y, Yokota T, Zhao H, Wong RJ, Stevenson DK, Taniguchi-Ikeda M, Nakamura H, Iijima K, Morioka I. Association of HMOX1 gene promoter polymorphisms with hyperbilirubinemia in the early neonatal period. Pediatr Int. 2015;57(4):645–9.View ArticlePubMedGoogle Scholar
  25. Kanai M, Akaba K, Sasaki A, Sato M, Harano T, Shibahara S, Kurachi H, Yoshida T, Hayasaka K. Neonatal hyperbilirubinemia in Japanese neonates: analysis of the heme oxygenase-1 gene and fetal hemoglobin composition in cord blood. Pediatr Res. 2003;54(2):165–71.View ArticlePubMedGoogle Scholar
  26. Huang CS, Chang PF, Huang MJ, Chen ES, Hung KL, Tsou KI. Relationship between bilirubin UDP-glucuronosyl transferase 1A1 gene and neonatal hyperbilirubinemia. Pediatr Res. 2002;52(4):601–5.View ArticlePubMedGoogle Scholar
  27. Long J, Zhang S, Fang X, Luo Y, Liu J. Neonatal hyperbilirubinemia and Gly71Arg mutation of UGT1A1 gene: a Chinese case–control study followed by systematic review of existing evidence. Acta Paediatr. 2011;100(7):966–71.View ArticlePubMedGoogle Scholar
  28. Maruo Y, Nishizawa K, Sato H, Doida Y, Shimada M. Association of neonatal hyperbilirubinemia with bilirubin UDP-glucuronosyltransferase polymorphism. Pediatrics. 1999;103(6 Pt 1):1224–7.View ArticlePubMedGoogle Scholar
  29. Hanchard NA, Skierka J, Weaver A, Karon BS, Matern D, Cook W, O'Kane DJ. UGT1A1 sequence variants and bilirubin levels in early postnatal life: a quantitative approach. BMC Med Genet. 2011;12:57.View ArticlePubMedPubMed CentralGoogle Scholar
  30. Liu J, Long J, Zhang S, Fang X, Luo Y. Polymorphic variants of SLCO1B1 in neonatal hyperbilirubinemia in China. Ital J Pediatr. 2013;39:49.View ArticlePubMedPubMed CentralGoogle Scholar
  31. Ko TM, Hwang WJ, Chen SH, Lee TY, Hsieh GY, Lee CY. Alpha-thalassemia minor and neonatal hyperbilirubinemia. J Formos Med Assoc. 1990;89(5):378–82.PubMedGoogle Scholar

Copyright

© The Author(s). 2016

Advertisement